Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis.
Coronado PJ, Gómez A, Iglesias E, Fasero M, Baquedano L, Sánchez S, Ramírez-Polo I, de la Viuda E, Otero B, Llaneza P, Mendoza N, Lubián DM; HMT Eligibility Criteria Group. Coronado PJ, et al. Among authors: llaneza p. Menopause. 2024 Mar 1;31(3):234-242. doi: 10.1097/GME.0000000000002317. Menopause. 2024. PMID: 38385734
What do TSECs provide in the menopausal hormone therapy?
Llaneza P, Calaf J, Jurado AR, Mendoza N, Otero B, Quereda F, Sánchez-Borrego R, Lubian D. Llaneza P, et al. Gynecol Endocrinol. 2018 Oct;34(10):826-832. doi: 10.1080/09513590.2018.1474869. Epub 2018 May 23. Gynecol Endocrinol. 2018. PMID: 29790381 Review.
Population-based survey on menopausal symptoms and treatment use.
Baquedano L, Coronado P, De la Viuda E, Sánchez S, Otero B, Ramírez I, Llaneza P, Mendoza N. Baquedano L, et al. Among authors: llaneza p. Climacteric. 2023 Feb;26(1):47-54. doi: 10.1080/13697137.2022.2139598. Epub 2022 Nov 9. Climacteric. 2023. PMID: 36351874
Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group.
Mendoza N, Ramírez I, de la Viuda E, Coronado P, Baquedano L, Llaneza P, Nieto V, Otero B, Sánchez-Méndez S, de Frutos VÁ, Andraca L, Barriga P, Benítez Z, Bombas T, Cancelo MJ, Cano A, Branco CC, Correa M, Doval JL, Fasero M, Fiol G, Garello NC, Genazzani AR, Gómez AI, Gómez MÁ, González S, Goulis DG, Guinot M, Hernández LR, Herrero S, Iglesias E, Jurado AR, Lete I, Lubián D, Martínez M, Nieto A, Nieto L, Palacios S, Pedreira M, Pérez-Campos E, Plá MJ, Presa J, Quereda F, Ribes M, Romero P, Roca B, Sánchez-Capilla A, Sánchez-Borrego R, Santaballa A, Santamaría A, Simoncini T, Tinahones F, Calaf J. Mendoza N, et al. Among authors: llaneza p. Maturitas. 2022 Dec;166:65-85. doi: 10.1016/j.maturitas.2022.08.008. Epub 2022 Aug 30. Maturitas. 2022. PMID: 36081216
Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review.
Fiol G, Lete I, Nieto L, Santaballa A, Pla MJ, Baquedano L, Calaf J, Coronado P, de la Viuda E, Llaneza P, Otero B, Sánchez-Méndez S, Ramírez I, Mendoza N; “HMT Elegibility Criteria Group”. Fiol G, et al. Among authors: llaneza p. J Clin Med. 2023 Aug 12;12(16):5263. doi: 10.3390/jcm12165263. J Clin Med. 2023. PMID: 37629305 Free PMC article. Review.
63 results